ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

Recruiting now · Phase 4

Conditions studied: Psoriasis

In brief

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Key facts

Study ID

NCT04347473

Run by

Psoriasis Treatment Center of Central New Jersey

People needed

25

Starts

2020-04-06

Expected to finish

2021-03-01

Last updated by the study team

2020-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female adult ≥ 18 years of age;
• Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by
• BSA 10%
• PGA ≥3
• PASI ≥12
• Must be a candidate for phototherapy and/or systemic therapy
• Females of childbearing potential (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.

You may not qualify if…

• Non-plaque forms of psoriasis
• Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
• Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial.
• Active or untreated latent tuberculosis (TB)

Where it is running

• Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.